SK hynix Inc. has fallen another 7% on the week to $143.73 — the third consecutive week of losses since the July 23 Q2 print — and the Street's first coordinated analyst coverage is landing into the decline rather than ahead of it.
The analyst picture is the most meaningful new development this week. Barclays and UBS both issued formal coverage on July 30, the day after the latest leg lower. Barclays' Simon Coles came in with an Overweight but trimmed the target to $300 from the $330 initiation level set just two weeks prior — a rapid downward adjustment that reflects how much the tape has moved. UBS initiated separately with a Buy and a $204 target, a more conservative anchor that sits closer to current levels. The consensus mean target is $245, implying more than 70% upside from Friday's close. That gap between target and price is wide by any measure, and it has widened further as the stock has continued to fall after each catalyst. The Street is constructive. The market is not listening.
The borrow market remains a non-story, though it is worth noting a modest shift in direction. Availability has tightened meaningfully this week — from around 310% two weeks ago to 185% now, the tightest reading since the Nasdaq listing — as short shares outstanding rose 8% on July 30 alone to roughly 18.4 million. Cost to borrow eased back to 0.84%, down sharply from the 12.9% spike seen on July 14 and the 4% level seen in mid-July, which confirms that the incremental short interest is being established cheaply rather than under any squeeze pressure. Availability at 185% is still well within normal range. There is no crowded short here, and the direction-of-travel bears watching but not alarm.
Options positioning tells the more pointed defensive story. The put/call ratio ended July at 1.69, the highest reading of the past month and well above the mid-July lows near 1.34. For context, the 52-week high is 3.28, hit on July 16 — the same week the cost-to-borrow spiked — so the current level is elevated but not extreme. The pattern suggests options buyers are paying for downside protection after two consecutive post-earnings drops: the July 23 Q2 flash print erased 8.3% and the July 29 detailed results added another 14.5% decline in Seoul. Hedging demand is real, even if short sellers are not the driving force.
The fundamental picture remains the central tension that prior notes have flagged, and nothing in this week's data resolves it. The trailing PE is now 4.7x. Price-to-book is 2.5x. EV/EBITDA is 0.36x — a distressed-cycle multiple on a company whose EPS surprise factor ranks in the 89th percentile and whose 90-day EPS momentum sits in the 77th. The ORTEX factor scores tell the same story: short score rank at 95th percentile reflects how low the short conviction is, not how high; the dividend score ranks at 99th; ev/ebit at 99th. The stock is cheap on almost every metric the model touches. BlackRock added 979,000 shares in the most recent filing period. Capital Research added 692,000. FMR added 891,000. The accumulation is quiet but consistent across multiple large institutional names.
The next scheduled event is the Q3 earnings print on October 29. Between now and then, the question is whether the $245 analyst consensus — itself a moving target, given Barclays already trimmed once inside a fortnight — stabilises, and whether the tightening in availability accelerates or reverses as the post-earnings dust settles.
See the live data behind this article on ORTEX.
Open SKHY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
